Today on The Fundamentals is Dr. Maria Castro, the R.C. Schneider collegiate professor of neurosurgery, and a professor of cell and developmental biology at the University of Michigan Medical School. Her research program aims to develop immunotherapies for primary and metastatic brain cancer, studying basic immune biology mechanisms leading to clinical implementation. She has been inducted into the American Association for the Advancement of Sciences, the Latin American Academy of Sciences, and the American Institute for Medical and Biological Engineering College of Fellows. She has won numerous awards for her contributions to basic science and cancer research and is a diversity ambassador for the Cancer Biology Graduate Training Program. You can learn more about Dr. Castro here, and you can follow her @castro2355_mg, the Rogel Cancer Center @UMRogelCancer, the department of neurosurgery @umichneuro, Michigan Neurscience Institute @UM_MNI and the department of cell and developmental biology @UMCDB on X

Experts in brain cancer outline current discoveries and offer a path of hope for glioblastoma treatment

Researchers recently revealed a new mechanism behind antiphospholipid syndrome that the investigators hope will eventually allow treatments to be targeted closer to the source of the problem.

Four faculty and two staff members from the departments of Anesthesiology, Neurology, Radiology and Surgery, and the Office of Graduate Medical Education (GME), are recipients of GME Awards for 2024

At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests

As guest editor for a themed journal issue, Lori Pierce helps highlight the multiple factors that can make cancer care and prevention more equitable and reduce the burden of this disease for all

Vaccination against the coronavirus was much lower in adults and children with sickle cell disease despite a higher risk of severe COVID-19.

Research from Michigan Medicine experts is shedding light and potentially expanding options for patients living with an aggressive childhood cancer.

Recently approved by the Food and Drug Administration, Pluvicto is a radionuclide-labelled drug administered to patients showing promising results.

How two newly approved gene therapies, including novel technology CRISPR, may help kids and adults with inherited blood disorders

A car accident at age 20 left Sahar Mashhour in the intensive care unit for three months. Almost six years later, Mashhour is still pursuing her passions proving that her disability doesn’t limit her ability, but instead helps her see life through a different lens.

Infants with hemophilia A who received monoclonal antibody emicizumab experienced few bleeding events and no serious complications, a study suggests.

Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way.

Technology developed at U-M uses sound waves to destroy tissue, providing a new type of cancer therapy